Oral Surveillance Study Alters Practice at VA Safety risks found in a postmarketing trial with the JAKi tofacitinib (Xeljanz) appear to have influenced prescribing patterns across the class for RA patients in the VA health system, researchers found. https://t.co/6WktHCkrI1 https://t.co/8wpAeLsBbw